Business
Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN
Met the primary endpoint, achieving statistically significant 68%
About this update from Apellis Pharmaceuticals, Inc.
[{"type":"text","content":"Met the primary endpoint, achieving statistically significant 68% (p","length":88,"tagName":"div"}]